About Us

Kadmon is a clinical-stage biopharmaceutical company that discovers, develops and delivers transformative therapies for unmet medical needs. We are developing treatments for immune and fibrotic diseases as well as immuno-oncology therapies.

Learn More

KD025

We have a deep understanding of the pathways involved in inflammation and fibrosis. Our late-stage product candidate, KD025, is an inhibitor of ROCK2, a signaling pathway that modulates key inflammatory and fibrotic processes. A pivotal study of KD025 is underway in patients with chronic graft-versus-host disease (cGVHD). A Phase 2 clinical trial of KD025 is also underway in patients with systemic sclerosis (SSc).

Read More